- Trial Phase
- Phase 2 (enrolling)
- Time to Market
- At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings
- Why 4/10
- No hard dated binary catalyst within the next ~12 months. The Phase 2 INFLO-2 trial is actively enrolling but has not yet specified a topline readout date. The Phase 1b safety data (the most recent catalyst) has already been reported. Nintedanib DPI is also one of several programs at MannKind, which has approved marketed products (Afrezza, Furoscix) that are nearer-term value drivers.
Watch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.
Price Chart
Executive Summary
MannKind (MNKD) is developing nintedanib DPI (MNKD-201), an inhaled dry-powder formulation of the oral IPF drug nintedanib (Boehringer Ingelheim's Ofev®), using its proprietary Technosphere inhalation platform. In July 2026, the company reported clean Phase 1b INFLO-1 safety/tolerability data — no serious adverse events, no GI side effects, no bronchospasm, and no discontinuations — a significant de-risking for the program. The global Phase 2 INFLO-2 trial (~210 patients) is now actively enrolling. While oral nintedanib is a ~$3B+ franchise constrained by GI tolerability issues, the inhaled approach could expand the addressable market if it confirms a differentiated safety profile. However, the program is still early-stage, with no Phase 2 efficacy data yet, and faces competition from Avalyn Pharma's inhaled nintedanib (AP02) program.
How It Works
Nintedanib is a tyrosine kinase inhibitor that blocks multiple growth factor receptors (VEGFR, FGFR, PDGFR) involved in the scarring and fibrosis process in the lungs. The oral version (Ofev®) is a standard-of-care for idiopathic pulmonary fibrosis (IPF) but causes frequent GI side effects like diarrhea and nausea because it's absorbed systemically. MannKind's dry powder inhaler (DPI) delivers nintedanib directly to the lungs via inhalation, aiming to achieve similar or better lung effects with much lower systemic exposure — potentially eliminating the GI toxicity that limits oral nintedanib use.
Trial Status
Phase 1b INFLO-1 completed July 2026 with positive safety/tolerability results (27 patients, 10 U.S. sites). Global Phase 2 INFLO-2 (~210 patients, ~85 sites worldwide) is actively enrolling — a randomized, double-blind, placebo-controlled trial with a 12-week treatment period and 24-week open-label extension. Primary endpoint is safety/tolerability; secondary endpoint includes FVC decline rate.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 INFLO-2 topline safety data (no date specified; actively enrolling)
- Phase 2 INFLO-2 interim or final efficacy data on FVC decline (12+ months out)
- Afrezza pediatric commercial ramp following May 2026 FDA approval
- Furoscix ReadyFlow commercial launch following July 2026 FDA approval
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MannKind Press Release MNKD ·Originating report